Based on its previously documented role, we tested whether the targeted inhibition of AKT was sufficient to eradicate the PD cells in our co-culture model by using a pan-AKT inhibitor, MK-2206, which has been shown to have clinical benefit in cancer patients [38]. This evidence concerns the gene AKT1 and cancer.